Startup profile · funding coverage
Undecimal Bio funding, valuation and investors
Uses synthetic biology and AI to discover extrahepatic siRNA-delivery conjugates.
Keep track of Undecimal Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed
$18M · October 13, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$18M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Cambridge, United Kingdom and Tel Aviv, Israel
Investors in latest funding
Lead: 4BIO Capital , IQ Capital
Other: Verve Ventures , Harel Tech , Entrée Capital , Kerna Ventures , Saras Capital
Overview
Biotechnology company developing an AI-enabled discovery platform for conjugates that deliver siRNA medicines to specific cell types beyond the liver.
Why Undecimal Bio is interesting
Extrahepatic delivery remains one of RNA medicine’s central bottlenecks; Undecimal is combining large functional screens with computational analysis to search for tissue-targeting conjugates.
Product & use cases
DELiveri screens large combinatorial libraries of candidate ligands and analyzes productive cellular uptake to identify conjugates capable of carrying siRNA into defined cell types.
Funding history (newest first)
Seed
2026-10-13 $18M- 4BIO Capital (lead)
- IQ Capital (lead)
- Verve Ventures (participant)
- Harel Tech (participant)
- Entrée Capital (participant)
- Kerna Ventures (participant)
- Saras Capital (participant)
Investors in our directory
Funds linked from Undecimal Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Undecimal Bio's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.